Sonpiretigene isteparvovec is the nonproprietary name for MOGENRY, formerly referred to in trials as MCO-010. It is built on ...

Retina Consultants of America (RCA) recently released its first State of Retina Care report—a survey-based assessment of the pressures facing community-based retina practices and of how affiliated ...

ESCRS 2026 data: patient selection and education may be key to aceclidine (VIZZ; LENZ Therapeutics) persistence. Romero emphasized that use of the drops is task-specific rather than a continuous ...

Alessandro Arrigo, MD, previews an ESCRS 2026 presentation on a patent-pending method that adapts blue light autofluorescence ...

In an interview at the 44th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), held September ...

Mfazo Hove, MD, FRCOphth, a consultant ophthalmologist based in London, has a personal perspective on the trifocal ...

Q3 2026 delivered advances in some closely watched pipeline products.

Artificial intelligence (AI) is set to reshape multiple corners of eye care, according to Jai Parekh, MD, MA, FAAO, who ...

The first patients were dosed in the global phase 3 ORBIT pivotal trial of linsitinib for thyroid eye disease (TED). The first patients were dosed in the global phase 3 ORBIT trial evaluating ...

Two-year data presented at ESCRS 2026 show the ELIOS excimer laser procedure sustained IOP reduction and kept most glaucoma ...

ESCRS 2026 real-world data: aceclidine (VIZZ; LENZ Therapeutics) drops show fast onset, high satisfaction for presbyopia.

At ESCRS 2026, Zoltan Z. Nagy, MD, reported that femtosecond laser trabeculotomy (FLigHT) cut intraocular pressure by 27% at 48 months in open-angle glaucoma, with a stable, incision-free safety ...